Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

NCT02315599 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

500

Enrollment

NIH

Sponsor class

Conditions

Pediatric Cancers
Hematologic Malignancies
Solid Tumors

Interventions

DRUG: anti-CD19 CAR

Sponsor

National Cancer Institute (NCI)